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Target Motion Variability and On-Line Positioning 
Accuracy during External-Beam Radiation Therapy 
of Prostate Cancer with an Endorectal Balloon Device 
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Purpose: To prospectively define the setup error and the interfraction prostate localization accuracy of the planning target vol-
ume (PTV) in the presence of an endorectal balloon (ERB) device. 
Patients and Methods: Weekly portal images (PIs) of 15 patients undergoing external-beam radiotherapy were analyzed. Dis-
placements of the isocenter and the center of the ERB were measured. The setup and target motion variability were assessed with 
regard to the position variability of the ERB. 
Results: The setup error was random and target motion variability was largest in the craniocaudal direction. The mean displace-
ment of the isocenter was 2.1 mm (± 1.2 mm SD [standard deviation]), 2.4 mm (± 2.2 mm SD), and 3.8 mm (± 4.0 mm SD) in the 
left-right, craniocaudal, and anteroposterior directions, respectively (p = 0.1). The mean displacement of the ERB was 2.0 mm 
(± 1.4 mm SD), 4.1 mm (± 2.0 mm SD), and 3.8 mm (± 3.3 mm SD; p = 0.03). Setup margin and internal margin contributed 
equally to the PTV margin. Cumulative placement insecurity of the field and the ERB together was 4.0 mm (± 2.1 mm SD) later-
ally, 6.4 mm (± 2.5 mm SD) craniocaudally, and 7.7 mm (± 7.0 mm SD) anteroposteriorly. The 95% CIs (confidence intervals) were 
2.9–5.2 mm, 5.1–7.8 mm, and 3.8–11.5 mm. In 35% of cases, the estimation of the dorsal margin exceeded 1 cm.
Conclusion: Margin estimate dorsally may exceed 1 cm and on-line position verification with an ERB cannot be recommended for 
dose escalation > 70 Gy. 
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Organmobilität und Lokalisationsbestimmung der Prostata unter Einsatz eines endorektalen Ballons 
bei der Radiotherapie des Prostatakarzinoms
Ziel: Analyse des Positionierungsfehlers und der Lokalisationsgenauigkeit der Prostata zwischen den Bestrahlungen unter der 
Verwendung eines endorektalen Ballons (ERB) zwecks Positionierungshilfe. 
Patienten und Methodik: Die sequentiellen Einstellungsaufnahmen von 15 Patienten, die in kurativer Absicht eine externe 
Radiotherapie erhielten, wurden analysiert. Die Positionierungsvariabilität des ERB wurde unter Berücksichtigung der Lagevaria-
bilität des Set-up und des Zielvolumens gemessen. 
Ergebnisse: Der Einstellungsfehler (systemischer Fehler) zeigte keine Prädispositionen in x-, y- oder z-Richtung. Die Bewegungsva-
riabilität in kraniokaudaler Richtung war am größten. Die Lagevariabilität des Feldzentrums betrug 2,1 mm (± 1,2 mm), 2,4 mm 
(± 2,2 mm) und 3,8 mm (± 4,0 mm) in seitlicher, kraniokaudaler und anteroposteriorer Richtung (p = 0,1). Der ERB zeigte eine La-
gevariabilität von 2 mm (± 1,4 mm), 4,1 mm (± 2,0 mm) und 3,8 mm (± 3,3 mm) seitlich, kraniokaudal und anteroposterior (p = 
0,03). Die Positionsvariabilität des Feldzentrums in Bezug auf die Lokalisation des ERB war vernachlässigbar. Zur kumulati-
ven Zielunsicherheit trugen der systemische und der spezifische Fehler gleichermaßen bei. Die durchschnittliche Lageunsicherheit 
des Feldes und des Ballons gemeinsam betrug 4,0 mm (± 2,1 mm) lateral, 6,4 mm (± 2,5 mm) kraniokaudal und 7,7 mm 
(± 7,0 mm) anteroposterior. Die 95%-Konfidenzintervalle betrugen 2.9–5.2 mm, 5.1–7.8 mm, und 3.8–11.5 mm. Der geschätzte 
Sicherheitsabstand in dorsaler Richtung lag in 35% der Fälle bei > 1 cm.
Schlussfolgerung: Um einen Sicherheitsrand von < 1 cm gegen dorsal zu erzielen, reicht ein ERB allein nicht aus. Für Therapien 
mit Dosen > 70 Gy empfehlen sich zusätzliche Positionierungs- und Positionsverifikationssysteme, um den dorsalen Sicherheits-
abstand klein halten zu können. 
Schlüsselwörter:  Prostatakarzinom · Endorektaler Ballon · Positionsgenauigkeit · PTV · Intensitätsmodulation 
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Introduction
On-line position verification of the prostate is a prerequisite 
for high-dose external-beam radiotherapy (EBRT) to the pros-
tate. Dose escalation improves biochemical relapse-free sur-
vival and conformal radiotherapy (CRT) decreases treat-
ment-related morbidity [5, 6, 9, 11–13, 22, 25, 26, 35]. CRT and 
multileaf collimators (MLCs) reduce the volume of normal tis-
sue included in the planning target volume (PTV) by up to 
40% compared to conventional radiotherapy (RT) and thus 
decrease the normal-tissue complication probability (NTCP) 
[10]. Reduced dose delivered to non-cancer tissue, however, is 
defined by the setup margin surrounding the cancer tissue in 
the clinical target volume (CTV). The PTV margin as defined 
by ICRU (Report No. 62) consists of two components, the in-
ternal margin (IM) reflecting anatomic position variability and 
the setup margin, defined by the daily positioning and machine 
geometry variability [16]. The IM accounts for changes in 
shape, size, and motion of the CTV, while the setup margin ac-
counts for errors in positioning. One of the major problems is 
the interfraction motion of the prostate affected by rectal and 
bladder filling and contractions of the pelvic floor [7, 18, 28, 30, 
33, 34].
Interfraction motion can be reduced with positioning de-
vices such as casts or leg holders, fixation devices such as en-
dorectal balloons (ERBs) or spacers [3, 14, 15, 31], by treating 
only patients with a full bladder (500 cm3 of fluids), and the use 
of laxatives to minimize pelvic organ filling and motion of the 
prostate [4, 27, 29]. Direct visualization before treatment with 
ultrasound or pretreatment session computed tomography 
(CT) scans has been evaluated [17]. Gold fiducial markers im-
planted in the prostate may also be used to assess interfraction 
mobility and allow on-line prostate position verification [19]. 
Implantation of markers, however, is an invasive procedure and 
carries a small but definitive risk of complications such as sep-
ticemia, hematuria, hemospermia, and rectal bleeding [1, 33].
In the present study, we prospectively evaluated the ability 
of an ERB device to reduce the posterior PTV margin and 
whether an ERB by itself would be suitable for dose escalation 
treatment without additional prostate positioning techniques.
Patients and Methods 
15 patients with non-metastatic node-negative adenocarcino-
ma of the prostate undergoing conformal EBRT with curative 
intent were investigated. The patients’ average age was 70.7 
years (range: 65–78 years). The mean prostate-specific antigen 
(PSA) at presentation was 25.4 ng/l (± 25.6 ng/l SD [standard 
deviation]; range: 0.4–106 ng/l). Five patients each presented 
with stage T1c, T2, and T3 disease. The median Gleason Score 
was 7 (range: 5–10). All patients had CT-based treatment 
planning and were treated as described previously [3]. An 
ERB was placed in the rectum and inflated with 60 cm3 of air, 
followed by RT planning (Pinnacle TM, Philips Laboratories 
GmbH, Düsseldorf, Germany) target delineation. Patients 
were treated using a four-field box technique with MLCs on a 
6-MV linear accelerator (Varian 600c or 6EX, Varian Associ-
ates, Palo Alto, CA, USA). After 50 Gy, the PTV margin was 
reduced. 70 Gy in 2 Gy per day over 7 weeks were applied. 
Portal images (PIs) were acquired using an electronic 
portal imaging device (EPID). The first image was acquired 
before delivering the first fraction and compared to the digi-
tally reconstructed radiograph (DRR) of the corresponding 
field. PIs were obtained weekly [2]. 
PIs were transferred with DICOM (Digital Imaging and 
Communication in Medicine) via a verifying system (Multi-Ac-
cess, Impact Medical system, Palo Alto, CA, USA) for our 
analysis. To depict the center of the radiation field, a grid set-
up was used. The ERB outline and the center of the balloon 
were defined. Measurements were taken from the isocenter 
and a fixed bony landmark to assess setup variations. Meas-
urements from the center of the ERB to the same bony land-
marks were used to determine the interfraction target mobili-
ty. The measurements recorded from the DRR served as 
baseline and any deviation recorded in any of the subsequent 
PIs was measured. 
Statistical Analysis 
SDs were calculated according to the formula S2 = Σ (X–M)/N, 
where X is the value of the score, M is the mean, and N is the 
number of scores. The 95% confidence intervals (CIs) were 
computed with Z = (t 0.95) × SEM (standard error of the 
mean). The comparison between the mean setup and target 
motion variation was assessed with Student’s paired t-test. 
Setup variations, as well as organ movement in the course of 
RT, were calculated using a repeated measures analysis of 
variance test.
Results 
Position of the Isocenter in Relation 
to the Symphysis Pubis 
The mean distance between the symphysis pubis (SP) and 
the center of the field in the lateral direction was 3.4 mm 
(± 1.1 mm SD), and the median 3.7 mm (range: 1.6–6.0 mm) 
with a 95% CI of 2.8–4.0 mm. In the craniocaudal direction, 
the average distance between the upper border of the SP 
and the center of the field was 2.9 mm (± 0.66 mm SD), and 
the median 12.2 mm (range: 2.7–23.1 mm) with a 95% CI of 
9.2–16.6 mm. In the anteroposterior direction, the center of 
the field averaged 56.3 mm (± 8.0 mm SD), with a median 
value of 54.0 mm (range: 44.3–70.6 mm) and a 95% CI of 
51.8–60.7 mm. Results are summarized in Table 1. 
Position of the Center of the ERB in Relation 
to the Symphysis Pubis 
As for the ERB, the mean distance between the SP and the 
center of the ERB in lateral direction was 2.8 mm (± 1.5 mm 
SD), and the median 2.9 mm (range: 0.4–5.4 mm) with a 95% CI 
of 2.0–3.6 mm. Craniocaudally, the mean distance between 
center of the ERB and the upper border of the SP was 12.0 mm 
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(± 6.5 mm SD), with a median of 12.6 mm (range: 3.2–22.9 mm) 
and a 95% CI of 8.5–15.6 mm. Finally, in the anteroposterior 
direction, the ERB was 98.1 mm dorsal of the SP (± 6.3 SD), 
with a median of 98.7 mm (range: 86.1–107.7 mm) and a 95% 
CI of 94.6–101.6 mm. Results are summarized in Table 2. 
Assessment of Setup Variations 
Mean displacement of the center of the field from its baseline 
position in the lateral direction was 2.1 mm (± 1.2 mm SD), 
with a median value of 2.1 mm (range: 0.2–4.8 mm). In the cra-
niocaudal direction, the displacement was 2.4 mm (± 2.2 mm 
SD), with a median of 1.5 mm (range: 0.5–7.8 mm). In the an-
teroposterior direction, displacement of the field center was 
3.8 mm (± 4.0 mm SD), with a median of 2.5 mm (range: 
0.1–16.3 mm). There were no significant differences between 
the displacement of the field center in x, y, or z (p = 0.1). 
Assessment of Target Mobility Variations 
The mean lateral displacement of the center of the balloon 
was 2.0 mm (± 1.4 mm SD), with a median of 1.6 mm (range: 
0.4–4.8 mm). In the craniocaudal direc-
tion, mean displacement was 4.1 mm 
(± 2.0 mm SD), with a median of 3.9 mm 
(range: 1.6–7.2 mm). Anteroposterior-
ly, mean displacement was 3.8 mm 
(± 3.3 mm SD), with a median of 2.9 mm 
(range: 0.4–11.7 mm). Overall differenc-
es were statistically significant (p = 0.03), 
especially the difference between the 
lateral and the craniocaudal variations 
(p = 0.007). No difference of the dis-
placement variability of the center of the 
balloon and the center of the ERB were 
found, and the contributions of the set- 
up margin and the IM to the final PTV 
margin were comparable (Table 3). 
The mean and the SD of the target 
mobility are shown for the lateral (Fig-
ure 1a), craniocaudal (Figure 1b), and 
anteroposterior (Figure 1c) directions. 
Variations exceeding 10 mm were re-
corded in 1.7%, 12.5%, and 17% of 
measurements in the lateral, craniocau-
dal, and anteroposterior directions of 
motion, respectively. 
Assessment of PTV Margins
Total combined displacement variability 
of the field and the ERB laterally was 4.0 
mm (± 2.1 mm SD), with a median of 
4.1 mm (range: 0.8–6.9 mm) and a 95% 
CI of 2.9–5.2 mm. In the craniocaudal 
direction, the displacement was 6.4 mm 
(± 2.5 mm SD), with a median of 7.0 mm 
(range: 2.3–9.6 mm) and a 95% CI of 5.1–7.8 mm. In the an-
teroposterior direction, the mean value was 7.7 mm (± 7.0 mm 
SD), with a median of 5.5 mm (range: 0.6–28 mm) and a 95% 
CI of 3.8–11.5 mm (Table 4). PTV margins were 5.2 mm later-
ally, 7.8 mm craniocaudally, and 11.5 mm anteroposteriorly. 
The PTV margin in the anteroposterior direction exceeded 
10 mm in 35% of incidences. 
Discussion 
Minimizing RT dose delivered to the rectal wall during cura-
tive treatment of prostate cancer is important to avoid unnec-
essary toxicity [20]. We and others have previously shown, 
that an ERB reduces prostate mobility and the dose of ioniz-
ing radiation delivered to the rectal mucosa [7, 15, 32]. We 
measured PTV margins in the absence of additional prostate 
localization techniques except an ERB. We found that inter-
nal motion and field setup variability in the presence of an 
ERB alone results in a suboptimal PTV margin in anteropos-
terior direction exceeding a positioning accuracy of 1 cm in 
one third of patients. 
Table 1. Distance of the field center to the symphysis pubis (SP). CI: confidence interval; 
SD: standard deviation. 
Tabelle 1. Position der Feldmitte in Bezug zur Symphyse (SP). CI: Konfidenzintervall; SD: Stan-
dardabweichung. 
SP–field center Lateral direction Craniocaudal direction Anteroposterior direction
Mean (± SD) 3.4 mm (± 1.1 mm) 2.9 mm (± 0.66 mm) 56.3 mm (± 8.0 mm)
Median (range) 3.7 mm (1.6–6.0 mm) 12.2 mm (2.7–23.1 mm) 54.0 mm (44.3–70.6 mm) 
95% CI 2.8–4.0 mm 9.2–16.6 mm 51.8–60.7 mm
Table 2. Distance of the center of the endorectal balloon (ERB) to the symphysis pubis (SP). 
CI: confidence interval; SD: standard deviation. 
Tabelle 2. Variabilität der Distanz zwischen Mitte des ERB zur Symphyse (SP). CI: Konfidenz-
intervall; ERB: endorektaler Ballon; SD: Standardabweichung. 
SP–ERB Lateral direction Craniocaudal direction Anteroposterior direction
Mean (± SD) 2.8 mm (± 1.5 mm) 12.0 mm (± 6.5 mm) 98.1 mm (± 6.3 mm)
Median (range) 2.9 mm (0.4–5.4 mm) 12.6 mm (3.2–22.9 mm) 98.7 mm (86.1–107.7 mm)
95% CI 2.0–3.6 mm 8.5–15.6 mm 94.6–101.6 mm
Table 3. Displacement of the center of the field and the center of the endorectal balloon (ERB) 
in relation to the symphysis pubis. SD: standard deviation. 
Tabelle 3. Positionsvariabilität der Feldmitte in Bezug zur Mitte des endorektalen Ballons (ERB). 
SD: Standardabweichung. 
Mean displacement Lateral direction Craniocaudal  Anteroposterior  p-value
(± SD)     direction direction
Field 2.1 mm (± 1.2 mm) 2.4 mm (± 2.2 mm) 3.8 mm (± 4.0 mm) 0.1
ERB 2.0 mm (± 1.4 mm) 4.1 mm (± 2.0 mm) 3.8 mm (± 3.3 mm) 0.03
p-value 0.9 0.07 0.9 
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We accepted the ERB mobility as a surrogate for prostate 
mobility in this study based on our previous analysis [7]. We 
assumed that the position variability of the ERB represents 
internal target positioning variability and the interfraction 
mobility. Overall, IM variability was comparable to the setup 
variability. However, besides the inaccuracy in anteroposteri-
or direction, the ERB seems insufficient for prostate location 
for the purpose of dose escalation, because the IM in cranio-
caudal direction exceeds the setup variability, which is consis-
tent with our previous study [3]. The imprecision in craniocau-
dal direction may be substantial for cases requiring treatment 
of the seminal vesicles.
Several authors reported on ERB and motion variability 
and PTV margins. McGary et al. assessed prostate displace-
ment in ten patients with an ERB during the course of inten-
sity-modulated radiation treatment (IMRT) [21]. The pros-
tate displacement in the anteroposterior and the lateral 
direction was shown to be in the order of ~1 mm. The SD of 
the craniocaudal displacements was 1.8 mm and comparable 
to the SD in the present study. In a comparative study by 
D’Amico et al., the mean displacement 
of the prostate with an ERB was 1.3 
(0–2.2) mm compared to 1.8 (0–9.1) mm 
(p = 0.03) without an ERB, and the 
ERB reduced prostate motion vari-
ability [8]. Maximum displacement was 
reduced from 4 mm to ≤ 1 mm using a 
balloon. Wachter et al. found that maxi-
mum displacements of posterior pros-
tate border (> 5 mm) were found in 
eight of ten patients without and in only 
two of ten patients with an ERB [32]. 
Table 4. Sum of the displacements of the center of the field and the center of the endorectal 
balloon (ERB) in relation to the symphysis pubis. CI: confidence interval; SD: standard deviation. 
Tabelle 4. Summe der Positionsveränderungen der Feldmitte und der Mitte des endorektalen 
Ballons in Bezug zur Symphyse. CI: Konfidenzintervall; SD: Standardabweichung. 
∑ (field + ERB)  Lateral  Craniocaudal  Anteroposterior
displacement direction direction direction
Mean (± SD) 4.0 mm (± 2.1 mm) 6.4 mm (± 2.5 mm) 7.7 mm (± 7.0 mm)
Median (range) 4.1 mm (0.8–6.9 mm) 7.0 mm (2.3–9.6 mm) 5.5 mm (0.6–28 mm)
95% CI 2.9–5.2 mm 5.1–7.8 mm 3.8–11.5 mm
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Figures 1a to 1c. Mean and SD of the endorectal balloon mobility in 
the lateral (a), craniocaudal (b), and anteroposterior (c) direction for 
individual patients. 
Abbildungen 1a bis 1c. Mobilität des endorektalen Ballons in lateraler 
(a), kraniokaudaler (b) und anteroposteriorer (c) Richtung (Mittelwert 
und SD). 
Figure 1a – Abbildung 1a 
Figure 1b – Abbildung 1b 
Figure 1c – Abbildung 1c 
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The balloon reduced the posterior rectal wall volume in the 
high-dose regions without changing exposure of the anterior 
half of the rectal wall. Van Lin et al. compared patients irradi-
ated using an ERB to patients without an ERB [31]. Patients 
had gold markers implanted, as well, and an off-line electron-
ic portal imaging correction protocol was used for prostate 
position verification; the fiducial markers were effective in 
reducing the systematic prostate displacements, whereas the 
ERB did not reduce the interfraction prostate motion. Patel 
et al. evaluated the volumes of the rectal wall and the bladder 
receiving high-dose RT in respect of presence or absence of 
an ERB for 3D-conformal RT, IMRT, and helical tomother-
apy [23, 24]. An ERB in 3D-CRT reduced the rectal volume 
by 40%, 42%, and 44% at doses of 60 Gy, 65 Gy, and 70 Gy, 
respectively. Interestingly, helical tomotherapy resulted in 
the smallest volume of the rectum irradiated to a high dose 
when compared to 3D-CRT. Recently, van Lin et al. reported 
that an ERB used during dose escalation resulted in signifi-
cant rectal wall sparing potentially reducing late rectal toxic-
ity [31]. 
Taken together, the PTV margin anteroposteriorly do 
not seem to be reduced to < 1 cm by the ERB. Thus, the ERB 
by itself is not sufficient for elimination of interfraction mo-
tion of the prostate in respect of the area of the anterior rec-
tal wall exposed to high-dose RT. Additional positioning 
techniques such as intraprostatic fiducial markers or on-line 
CT imaging may reduce PTV margins sufficiently for dose 
escalation. 
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